"dual orexin receptor inhibitors"

Dual orexin receptor antagonists (also called dual orexin receptor inhibitors or DORAs) are a newer class of sleep medicines that promote sleep by blocking both orexin-1 and orexin-2 receptors, dampening the brain's wakefulness drive rather than acting as sedatives.[1] [2]

What they are

Dual orexin receptor antagonists block the action of orexin A and B neuropeptides at both orexin receptor 1 (OX1R) and receptor 2 (OX2R), which are key regulators of wakefulness. By inhibiting this wake-promoting system, they facilitate both sleep onset and sleep maintenance without directly enhancing GABA like benzodiazepines and "Z-drugs."[3] [4] [1]

Approved and investigational drugs

Several DORAs are in clinical use or advanced development for insomnia and related conditions. Key examples include:[2] [3]

- Suvorexant (first FDA-approved DORA, indicated for sleep-onset and sleep-maintenance insomnia).[4] [2]
- Lemborexant and daridorexant (newer DORAs for chronic insomnia, with dose-dependent effects on total sleep time and wake after sleep onset).[2] [3]
- Almorexant and filorexant have been studied but are not widely marketed.[2]

Efficacy in insomnia

Randomized controlled trials and meta-analyses show that DORAs improve total sleep time, reduce sleep latency (time to fall asleep), and decrease wake after sleep onset versus placebo. Higher doses generally produce larger improvements, although optimal dosing balances benefit with next-day somnolence risk.[3] [2]

Safety and tolerability

Across trials, DORAs are usually well tolerated, with common adverse effects including somnolence, headache, and nasopharyngitis, most often mild. Unlike many traditional hypnotics, they appear to carry lower risks of respiratory depression, rebound insomnia, and dependence, though long-term and comorbidity data are still being accumulated.[4] [3] [2]

Emerging uses

Because orexin signaling is involved in arousal and possibly clearance of brain metabolites, DORAs are being explored for sleep disturbances and potential disease-modifying effects in conditions like Alzheimer's disease. They are also of interest wherever pathological hyperarousal contributes to insomnia or fragmented sleep.[5] [3]

⁂

Compare suvorexant and lemborexant efficacy and dosing

Suvorexant and lemborexant are both effective dual orexin receptor antagonists for insomnia, but lemborexant generally shows stronger sleep-maintenance effects at approved doses, while suvorexant has a slightly more conservative dosing range with more age-based adjustment.[11] [12] [13]

Usual dosing

- **Suvorexant (Belsomra):** Typical starting dose 10 mg once nightly, taken within 30 minutes of bedtime with at least 7 hours available for sleep; may increase up to 20 mg if needed, with lower maximums when used with strong CYP3A inhibitors or in some older or debilitated patients.[14] [11]
- **Lemborexant (Dayvigo):** Usual starting dose 5 mg once nightly immediately before bed, with at least 7 hours available for sleep; may increase to 10 mg if needed, though many guidelines recommend staying at 5 mg in adults ≥65 because of somnolence risk.[15] [16]
- In comparative reviews, lemborexant 10 mg provides only modest extra efficacy over 5 mg but increases next-day somnolence, supporting 5 mg as the main dose for most patients.[13] [17]

Efficacy comparison

- Phase 3 trials show suvorexant 15–20 mg improves sleep onset and maintenance versus placebo, with reductions in latency to persistent sleep and wake after sleep onset and increases in total sleep time.[18] [19] [20]
- Lemborexant 5–10 mg improves latency to persistent sleep, wake after sleep onset, sleep efficiency, and patient-reported outcomes versus placebo and zolpidem controlled-release, with particularly strong effects on sleep maintenance metrics.[21] [15] [13]
- Network meta-analyses and head-to-head observational data generally rank lemborexant (especially 10 mg) above suvorexant for increasing total sleep time and reducing wake after sleep onset, although absolute differences are modest and all findings must be interpreted in the context of different trials and small direct comparative samples.[12] [22] [23] [13]

Safety and tolerability

- Both drugs commonly cause dose-related somnolence; suvorexant can also produce next-day impairment, especially at higher doses, which led to regulatory preference for the lower 10–20 mg range.[24] [20] [11]
- Observational and retrospective comparisons suggest lemborexant may have slightly fewer early-treatment side effects and better initial sleep duration than suvorexant, though differences are small and not always statistically significant.[25] [26] [12]
- For both agents, caution is advised with other CNS depressants, significant hepatic impairment, or conditions with compromised respiration, and they should only be used when a full night's sleep is feasible.[16] [11] [14]

At-a-glance comparison

Feature	Suvorexant	Lemborexant
Typical starting dose	10 mg nightly. [11] [14]	5 mg nightly. [15] [16]
Usual max dose	20 mg nightly (lower with CYP3A issues). [11] [14]	10 mg nightly; 5 mg often preferred in ≥65. [16] [17]
Key efficacy profile	Improves onset and maintenance vs placebo. [18] [19]	Strong gains in maintenance and onset vs placebo and zolpidem. [13] [21]
Relative efficacy vs other DORAs	Generally less robust than lemborexant in network/meta-analyses. [12] [13] [23]	Often ranks highest for TST, WASO, and sleep efficiency. [13] [22] [23]
Common adverse effects	Somnolence, next-day impairment at higher doses. [24] [11]	Somnolence; 10 mg increases risk vs 5 mg. [15] [16] [17]

⁂

for prevention of AD

Current evidence does not support using suvorexant or lemborexant specifically to prevent Alzheimer's disease (AD) in routine clinical practice, but dual orexin receptor antagonists (DORAs) are being actively studied as a potential preventive strategy via effects on sleep and AD biomarkers.[31] [32]

What is known so far

Sleep disruption and hyperactive orexin signaling are linked to higher amyloid-β and tau burden, and orexin blockade in animal models reduces amyloid deposition and tau pathology while improving sleep. In mice, lemborexant has reduced tau deposition and neurodegeneration, while suvorexant and related DORAs have limited cognitive impairment and amyloid accumulation in transgenic AD models.[33] [34] [35] [36] [37]

Human data with existing DORAs

In people with AD dementia or prodromal AD, suvorexant and lemborexant improve insomnia metrics such as total sleep time, wake after sleep onset, and sleep efficiency, with generally favorable safety. A small mechanistic study in cognitively unimpaired or at-risk adults found that suvorexant acutely lowered cerebrospinal fluid amyloid-β and phosphorylated tau levels, suggesting a direct effect on AD-related proteins but not yet proving clinical prevention.[38] [39] [40] [41] [42] [43]

Ongoing prevention-focused trials

A phase II prevention trial (PAD-DORA) is testing daridorexant 50 mg versus placebo for 12 months in older adults without dementia but at risk for AD, with primary outcomes focused on plasma tau and amyloid ratios and secondary cognitive and sleep measures. Another planned trial is evaluating lemborexant in cognitively normal older adults with amyloid deposition to see whether chronic DORA treatment favorably shifts AD biomarkers.[44] [32] [45] [46] [31]

Practical implications now

Reviews emphasize that DORAs should currently be viewed as sleep treatments that may have additional biomarker benefits, not as established disease-modifying or preventive therapies. Outside of clinical trials, their role in AD prevention remains unproven, so decisions to use suvorexant, lemborexant, or daridorexant should be based on insomnia severity, safety, comorbidities, and guideline-based management rather than on hoped-for AD prevention.[40] [36] [47] [42] [31] [38]

⁂

Design of clinical trials testing DORAs for AD prevention

DORAs for Alzheimer's disease (AD) prevention are being tested in mid- to late-life adults at elevated AD risk, focusing on biomarker change (amyloid and tau) and sleep outcomes over 1–2 years rather than dementia incidence.[51] [52]

Target population and inclusion

Trials enroll cognitively normal or mildly impaired older adults (commonly 55–80 years) with evidence of increased AD risk, such as positive amyloid PET or plasma/CSF biomarkers, APOE ε4 carriage, family history, or vascular risk. Many protocols also require clinically relevant insomnia or sleep disturbance, aligning with the drugs' approved indication and mechanistic rationale linking poor sleep, orexin activity, and AD pathology.[52] [53] [54] [55] [51]

Interventions and comparators

DORAs (e.g., daridorexant, lemborexant) are given nightly at doses similar to or slightly higher than insomnia doses (for daridorexant, 50 mg vs placebo in PAD-DORA) for 12–24 months, taken before bedtime with adequate sleep opportunity. Placebo controls are standard; some trials stratify randomization by biomarker status or APOE ε4, and allow background stable hypnotics or antidepressants with careful monitoring to avoid confounding sleep effects.[56] [57] [51] [52]

Primary and secondary outcomes

Because incident dementia would require very long, large studies, primary endpoints are typically biomarker changes: plasma or CSF phosphorylated tau, total tau, and amyloid-β ratios, sometimes paired with neurofilament light or neuroimaging markers (amyloid or tau PET, hippocampal atrophy). Secondary outcomes commonly include:[54] [51] [52]

- Polysomnography or actigraphy-based sleep parameters and sleep diaries
- Cognitive composites (e.g., PACC-style or domain-specific batteries)
- Patient-reported sleep quality and daytime function, plus standard safety and tolerability measures.[55] [58] [51]

Trial design features

Most studies use randomized, double-blind, placebo-controlled, parallel-group designs with 1:1 allocation and prespecified interim safety reviews. Sample sizes are powered to detect modest biomarker effect sizes (e.g., 20–30% change in plasma p-tau) rather than clinical endpoints, with enrichment strategies (amyloid-positive, APOE ε4–positive) improving statistical power and relevance to preclinical AD.[53] [51] [52] [54]

Follow-up, durability, and extension

Follow-up includes regular safety visits and biomarker sampling (e.g., baseline, 6–12-month intervals, end of treatment), with cognitive and sleep assessments at similar time points. Many protocols plan open-label extensions to assess longer-term safety and persistence or reversibility of biomarker and sleep effects, while participants continue standard lifestyle and risk-factor management recommended for brain health.[51] [52] [55] [56]

⁂

How daridorexant differs from suvorexant and lemborexant for prevention

Daridorexant is being positioned more directly as a brain-health and biomarker-focused prevention candidate than suvorexant or lemborexant, mainly because of its pharmacologic profile, daytime function data, and the specific design of the PAD-DORA prevention trial.[59] [60]

Pharmacologic and clinical differences relevant to prevention

Daridorexant has a relatively shorter half-life and a dosing range (25–50 mg) that improves sleep while preserving or even improving daytime functioning, which is attractive for long-term use in otherwise non-insomniac at-risk adults. Network meta-analysis suggests daridorexant 50 mg provides strong improvements in total sleep time with a favorable somnolence profile compared with suvorexant 20/15 mg and lemborexant 10 mg, which can have more next-day sleepiness at higher doses.[61] [62] [63] [64] [65] [66]

Prevention-trial design: daridorexant vs others

The PAD-DORA trial tests daridorexant 50 mg nightly for 12 months in 240 adults without AD dementia, regardless of whether they have insomnia, with the primary endpoint being change in plasma p-tau181/non-phosphorylated tau181 ratio. In contrast, suvorexant and lemborexant studies in AD populations to date have largely focused on treating insomnia or agitation and on short-term CSF amyloid/tau changes, not on a dedicated, year-long biomarker-driven prevention design in cognitively normal at-risk adults.[60] [67] [68] [69] [59]

Target population and rationale

Daridorexant prevention trials enroll community-dwelling older adults at elevated AD risk (e.g., age, biomarker or family-history enrichment) but not limited to those with clinically significant insomnia, reflecting a strategy to use DORAs as disease-modifying adjuncts rather than pure hypnotics. Suvorexant and lemborexant work through the same orexin pathway, but existing human data and trial plans keep them mainly in a symptomatic sleep-treatment role, with AD prevention considered exploratory or secondary.[70] [67] [71] [72] [59] [60]

Biomarker focus and mechanistic framing

PAD-DORA's primary outcome is a tau ratio, with additional plasma AD biomarkers, cognition, and detailed sleep measures as secondary endpoints, explicitly aiming to test whether chronic daridorexant can shift core AD biology. Earlier suvorexant work has shown acute reductions in CSF amyloid-β and phosphorylated tau after short-term dosing, and lemborexant has shown neuroprotective signals in animal models, but neither currently has a large, prospective, biomarker-primary prevention trial comparable to daridorexant's program.[68] [69] [73] [59] [60]

Practical implications

All three DORAs remain unproven for AD prevention, but daridorexant is the only one with a purpose-built, year-long randomized prevention trial in non-demented adults, making it the leading test case for this indication. For now, suvorexant, lemborexant, and daridorexant should be chosen based on insomnia characteristics, safety, and regulatory status, with prevention use restricted to clinical trials.[64] [74] [75] [76] [59] [70]

⁂

Differences in blood brain barrier penetration among the three DORAs

All three marketed DORAs (suvorexant, lemborexant, daridorexant) are highly lipophilic, CNS-penetrant drugs, but they differ in receptor affinity and pharmacokinetics more than in any clearly quantified, clinically relevant difference in blood–brain barrier (BBB) penetration itself.[85] [86]

What is known and what is not

Preclinical and clinical pharmacology papers emphasize that all three agents were designed to cross the BBB efficiently and reach brain orexin receptors at low nanomolar concentrations. None of the major comparative reviews provides head-to-head human data on brain-to-plasma concentration ratios, so precise ranking of BBB penetration (e.g., "lemborexant > daridorexant > suvorexant") is not evidence-based at this time.[86] [87] [85]

Relative receptor/PK features often mistaken for BBB differences

- Suvorexant has high lipophilicity and a relatively long effective half-life, leading to sustained receptor occupancy but also more potential next-day effects at higher doses.[85] [86]
- Lemborexant shows very high affinity for OX2R with potent CNS activity at low doses (5–10 mg), reflecting strong central target engagement but not a separately quantified BBB advantage.[88] [85]
- Daridorexant was optimized for shorter half-life and a balance between strong nighttime receptor occupancy and reduced next-day residual effect, again pointing to pharmacokinetic tuning rather than uniquely superior BBB crossing.[89] [85]

Practical takeaway

Current literature supports that all three DORAs cross the BBB effectively and achieve therapeutically relevant central concentrations, but available data do not justify a firm hierarchy in BBB penetration among suvorexant, lemborexant, and daridorexant. Differences in clinical profile are better attributed to receptor selectivity, intrinsic potency, dosing, and elimination half-life than to documented differences in BBB permeability.[87] [90] [86] [85]

⁂

Optimal duration of DORA treatment for prevention outcomes

There is no established "optimal" duration of dual orexin receptor antagonist (DORA) treatment for Alzheimer's disease (AD) prevention; current evidence only supports hypotheses and early-phase trial designs, not definitive clinical guidance.[91] [92]

What trials are actually doing

- The daridorexant PAD-DORA prevention trial treats cognitively intact, at-risk adults for 12 months nightly, with plasma tau and amyloid ratios as primary biological outcomes and cognitive and sleep measures as secondary endpoints.[93] [94] [95]
- An adaptive phase II lemborexant trial in amyloid-positive, cognitively normal older adults is using approximately 6 months of nightly treatment to test feasibility and biomarker shifts (CSF and plasma AD markers).[96] [97]
- Acute suvorexant studies expose participants for only days to weeks to examine short-term CSF or plasma amyloid-β and tau changes, not long-term clinical outcomes.[98] [99] [100]

Insights from mechanistic and animal data

- Preclinical work in APP/PS1 mice generally uses chronic DORA administration over months of rodent lifespan, showing reduced amyloid plaques, tau pathology, and cognitive impairment when sleep is durably improved.[101] [102] [91]
- Reviews therefore argue that any preventive effect is likely to require long-term, continuous nightly treatment to maintain better sleep and lower cumulative amyloid/tau burden, but they do not define a specific minimum duration in humans.[103] [102] [91]

Provisional duration targets

- Expert overviews currently frame 6–12 months as the minimum needed in phase II trials to detect meaningful changes in blood or CSF biomarkers, with the expectation that phase III prevention trials may need multi-year exposure (e.g., 2–5 years) to test effects on clinical progression.[99] [104] [92]
- Because no completed prevention trial has yet shown that any specific treatment length reduces incident dementia or sustained cognitive decline, any duration beyond trial protocols remains speculative and should be pursued only in research settings.[92] [93] [91]

Practical bottom line

Right now, “optimal duration” for DORA use in AD prevention is defined by trial protocols (months to a year for biomarker change) rather than by proven clinical benefit, and longer, multi-year data will be required before a standard preventive treatment duration can be recommended. Outside of trials, DORAs should be used to treat insomnia according to approved indications, not for presumed long-term AD prevention.[94] [105] [93] [91] [92]

⁂

“amyloid/tau burden” **is this improvement a result of better sleep or some other aspect of the DORA drugs**

Most of the observed reduction in amyloid and tau with DORAs appears to be mediated by improved sleep and reduced orexin-driven hyperarousal, but there is also emerging evidence for more direct orexin-pathway effects on these proteins that may not be purely secondary to sleep. [112] [113]

Sleep-mediated mechanisms

Chronic sleep loss and circadian disruption increase interstitial and CSF amyloid-β levels, accelerate plaque formation, and raise CSF tau and phospho-tau, partly by impairing glymphatic and microglial clearance. In mouse AD models, daily DORA treatment lengthens consolidated sleep and correspondingly reduces amyloid plaque and tau deposition across multiple brain regions, supporting the idea that “normalizing” sleep is a primary driver of lower protein burden. [114] [115] [116] [117] [112]

Evidence for more direct orexin-pathway effects

Orexin itself can promote amyloid production and tau phosphorylation, and higher orexin-A levels in humans correlate with higher CSF amyloid-β and phospho-tau even after adjusting for measured sleep characteristics. In transgenic and seeding models, knocking down orexin signaling or blocking orexin receptors (especially OX2R) reduces tau spreading and related neuroinflammation, and acute suvorexant dosing in humans can lower CSF amyloid-β and phospho-tau over hours, a timescale too short to be fully explained by structural sleep changes alone. [118] [119] [120] [113] [121] [112]

Integrated view

Current reviews conclude that DORAs likely reduce amyloid/tau burden through a combination of mechanisms: (1) sustained improvement in sleep quantity/architecture and glymphatic clearance, and (2) direct modulation of orexin-driven neuronal activity, microglial function, and tau phosphorylation pathways. The relative contribution of sleep versus direct orexin signaling remains uncertain, but both are considered relevant when interpreting biomarker improvements in prevention-oriented DORA trials. [116] [122] [123] [114] [112]

⁂

“Orexin” **are there any peptides that inhibit orexin**

There are no well-established endogenous “anti-orexin” peptides that physiologically inhibit orexin in the same way orexin itself acts as a peptide agonist; instead, inhibition of orexin signaling is mainly achieved pharmacologically with small-molecule receptor antagonists rather than peptides. [132] [133]

Endogenous regulation

Orexin A and orexin B are themselves excitatory neuropeptides that activate OX1R and OX2R; they do not have known endogenous peptide antagonists that bind orexin receptors to block them in a specific, high-affinity way comparable to drug antagonists. Orexin neuron activity is down-regulated indirectly by other neuromodulators (e.g., GABAergic input, metabolic and circadian signals), but these are not orexin-targeted inhibitory peptides in the narrow sense of "orexin-blocking peptides."[134] [133] [135]

Pharmacologic inhibitors

All clinically used orexin "inhibitors" are small molecules (dual or selective orexin receptor antagonists such as suvorexant, lemborexant, daridorexant, and others in development) that occupy OX1R/OX2R and prevent orexin peptides from activating them. Experimental peptide-like tools in the literature are primarily orexin agonists or modified orexin analogues rather than therapeutic peptide antagonists, and no peptide-based orexin inhibitor is currently in clinical use.[136] [137] [132] [134]

⁂

Evidence for orexin auto-inhibition by other hypothalamic peptides

There is clear evidence that orexin neurons are inhibited by other hypothalamic peptides and local circuits, but this is circuit-level feedback rather than a simple "auto-inhibitory orexin peptide."[142] [143]

Melanin-concentrating hormone (MCH)

Melanin-concentrating hormone neurons in the lateral hypothalamus send projections that directly inhibit orexin neurons. MCH acts via MCH receptors (and often co-released GABA) to suppress orexin cell firing, promoting sleep and helping to switch the network from arousal (orexin-dominant) to sleep (MCH-dominant) states.[144] [145] [142]

Dynorphin and local GABA

Orexin neurons co-release dynorphin and GABA, which can participate in local inhibitory feedback loops. Dynorphin can oppose orexin's excitatory actions in downstream targets (such as ventral tegmental area and paraventricular nucleus), effectively dampening orexin-driven excitation when both are co-released, though this is mostly demonstrated on postsynaptic targets rather than as direct inhibition of orexin neurons themselves.[146] [145] [147] [143] [148]

Other hypothalamic inputs

Local GABAergic neurons in the lateral hypothalamus provide strong inhibitory synaptic input onto orexin neurons, helping silence them during sleep. Additional neuromodulators such as neuropeptide Y and others can indirectly reduce orexin activity by inhibiting neighboring circuits, further contributing to homeostatic control of arousal.[149] [150] [143] [151] [152]

⁂

Does neuropeptide Y inhibit orexin signaling directly in vivo

Yes. Neuropeptide Y (NPY) directly inhibits orexin (hypocretin) neurons in vivo and ex vivo, acting at the level of the orexin cells themselves rather than only upstream.[162] [163]

Direct actions on orexin neurons

Slice electrophysiology from mouse lateral hypothalamus shows that NPY hyperpolarizes identified orexin neurons, markedly reduces their firing rate, and activates a G-protein–gated inwardly rectifying potassium (GIRK) current via Y1 receptors, indicating a direct postsynaptic inhibitory effect. The same studies demonstrate additional presynaptic actions, with NPY reducing glutamatergic input to orexin cells via Y2/Y5 receptors, further dampening orexin neuron excitability.[164] [165] [162]

In vivo relevance

Anatomical and physiological work indicates that NPY-expressing arcuate and lateral hypothalamic neurons project to and innervate orexin neurons, providing a tonic inhibitory influence on the hypothalamic arousal system that links metabolic state to vigilance. Reviews of orexin circuitry therefore describe NPY as a physiologically important peptide brake on orexin signaling, modulating arousal, feeding, and energy homeostasis.[163] [166] [167]

⁂

does DSIP (δ-Sleep Inducing Peptide) affect orexin

There is no clear evidence that δ-sleep–inducing peptide (DSIP) directly modulates orexin neurons or orexin receptor signaling in vivo; any interaction, if it exists, is at most indirect through broader sleep–wake and stress circuits.[182] [183]

What is known about DSIP

DSIP is a small neuropeptide originally described for its ability to increase delta-wave sleep and has since been linked to modulation of GABA and NMDA receptors, stress responses, and respiration. Human and animal studies show DSIP can alter sleep architecture and reduce locomotor activity, but they do not report direct recordings from orexin neurons or orexin receptor–specific effects.[184] [185] [186] [182]

Relationship between DSIP and orexin markers

Correlative work in cerebrospinal fluid has found that orexin levels can covary with DSIP-like immunoreactivity in certain psychiatric populations, suggesting that both peptides participate in overlapping stress and arousal networks rather than a one-way inhibitory relationship. Reviews of orexin circuitry that catalog known inhibitory inputs (e.g., GABA, melanin-concentrating hormone, neuropeptide Y, serotonin) do not list DSIP as a defined pre- or postsynaptic regulator of orexin cells.[187] [183] [188] [189] [190]

Practical interpretation

Current literature therefore supports viewing DSIP as a general sleep- and stress-modulating peptide, not as a characterized orexin-targeting inhibitor akin to neuropeptide Y or MCH. Any orexin-related changes observed alongside DSIP are best interpreted as indirect or associative until direct electrophysiologic or receptor-level data are published.[185] [191] [183] [182] [187]

⁂

How does DSIP affect sleep stages that orexin regulates

Available data suggest DSIP modestly promotes deeper non-REM (NREM) sleep and can alter REM timing, which functionally opposes orexin's arousal-promoting role, but the effects are weaker and far less consistent than those seen with direct orexin antagonists.[203] [204]

DSIP effects on NREM (especially slow-wave) sleep

Early human and animal studies reported that DSIP or DSIP analogs can increase delta-wave (slow-wave) activity and total time in deeper NREM stages, particularly in individuals with disturbed sleep. This pattern aligns with what would be expected from reducing orexin-driven wakefulness, but these studies did not measure orexin directly, so the linkage is inferred rather than demonstrated.[205] [206] [203]

DSIP and REM sleep

Some polysomnographic work shows DSIP can shorten sleep latency and shift REM onset later in the night, effectively consolidating NREM before REM appears, again compatible with reduced arousal pressure. However, REM-related findings are variable across small trials, and they are not systematically tied to orexin measures the way modern DORAs are.[206] [207] [208] [203]

Comparison to orexin's role

Orexin promotes wake and suppresses entry into both NREM and REM, stabilizing wakefulness and facilitating transitions out of sleep. DSIP's reported increases in delta activity and NREM continuity therefore move sleep architecture in the opposite direction of orexin, but current data do not show that DSIP achieves this by directly acting on orexin neurons or receptors, only that its net stage pattern partially counters orexin's usual effects.[204] [209] [210] [203]

⁂

Which brain regions coexpress DSIP and orexin pathways

DSIP and orexin pathways overlap anatomically in broad regions such as the hypothalamus and basal forebrain, but there is no strong evidence that DSIP is coexpressed within orexin neurons themselves or in a tightly coupled orexin microcircuit.[211] [212]

Regions with DSIP and orexin presence

DSIP-like immunoreactivity is reported in neurosecretory nuclei of the hypothalamus, basal forebrain, and pituitary, including areas involved in neuroendocrine control rather than classic sleep–wake switching alone. Orexin neurons, by contrast, are concentrated in the lateral and perifornical hypothalamus with widespread projections to cortex, basal forebrain, brainstem arousal centers, and autonomic nuclei.[212] [213] [214] [215]

Areas of probable pathway overlap

DSIP-like peptide and orexin projections can both be found in:

- Hypothalamic regions involved in endocrine and autonomic regulation (e.g., paraventricular and other neurosecretory nuclei).[216] [217]
- Basal forebrain and limbic structures where DSIP has been detected and orexin fibers are known to terminate.[218] [217] [214]

These overlaps imply that neurons in shared target regions can be exposed to both DSIP-like peptides and orexin, but current histochemical work has not demonstrated consistent cellular coexpression (same neuron containing both DSIP and orexin) or a defined, shared microcircuit.

Interpretation

Current reviews describe DSIP's distribution as overlapping with many peptide systems (MCH, ACTH, etc.) without highlighting a specific pairing with orexin, while orexin circuit maps do not list DSIP as a major co-transmitter or input. The main conclusion is that DSIP and orexin influence some of the same brain territories (hypothalamus, basal forebrain, pituitary outputs), but their anatomical relationship is parallel rather than clearly coexpressed within a single, well-defined pathway.[219] [215] [218] [212]

⁂

1. https://www.sciencedirect.com/topics/neuroscience/dual-orexin-receptor-antagonist
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10232020/
3. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1070522/full
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3989084/
5. https://www.nature.com/articles/s44323-025-00025-5
6. https://www.cpd.utoronto.ca/cmsconference/2025-conference/industry-symposia/

7. https://go.drugbank.com/categories/DBCAT001938
8. https://www.cs.utep.edu/vladik/utepnmsu17posters.pdf
9. https://www.facebook.com/groups/clinicalnotes/posts/1848148718921166/
10. https://en.wikipedia.org/wiki/Orexin_antagonist
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4772996/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11114349/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10394202/
14. https://www.mayoclinic.org/drugs-supplements/suvorexant-oral-route/description/drg-20113017
15. https://jcsm.aasm.org/doi/10.5664/jcsm.6800
16. https://www.aafp.org/pubs/afp/issues/2021/0215/p241.html
17. https://academic.oup.com/ijpp/advance-article/doi/10.1093/ijpp/riaf077/8266843?searchresult=1
18. https://jcsm.aasm.org/doi/10.5664/jcsm.6116
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8896749/
20. https://pubmed.ncbi.nlm.nih.gov/24680372/
21. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2758000
22. https://www.sciencedirect.com/science/article/abs/pii/S0022395620304908
23. https://www.nature.com/articles/s41398-025-03439-8
24. https://www.aafp.org/pubs/afp/issues/2016/0615/p1016.html
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC11541064/
26. https://pubmed.ncbi.nlm.nih.gov/39512953/
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4591519/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9886170/
29. https://onlinelibrary.wiley.com/doi/full/10.1002/pcn5.85
30. https://jcsm.aasm.org/doi/full/10.5664/jcsm.6116
31. https://pubmed.ncbi.nlm.nih.gov/39365407/
32. https://clinicaltrials.gov/study/NCT07213349
33. https://rupress.org/jem/article/211/13/2487/41470/Potential-role-of-orexin-and-sleep-modulation-in
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710117/
35. https://www.biorxiv.org/content/10.1101/2025.01.28.635390v1
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC11979663/
37. https://www.sciencedirect.com/science/article/abs/pii/S1389945724003411
38. https://www.sciencedirect.com/science/article/abs/pii/S1064748124004809
39. https://www.nih.gov/news-events/nih-research-matters/insomnia-drug-may-lower-levels-alzheimers-proteins
40. https://pubmed.ncbi.nlm.nih.gov/39462720/
41. https://karger.com/books/book/380/chapter/5564388/Hypocretin-Orexin-Sleep-and-Alzheimer-s-Disease
42. https://www.mypcnow.org/fast-fact/orexin-receptor-antagonists-for-insomnia-in-patients-with-serious-illness/

43. https://www.alzheimers.gov/news/insomnia-drug-may-lower-levels-alzheimers-proteins
44. https://www.trialx.com/clinical-trials/listings/286861/dora-and-lp-in-alzheimers-disease-biomarkers/
45. https://ctv.veeva.com/study/daridorexant-for-alzheimer-disease-prevention
46. https://www.isrctn.com/ISRCTN63918057
47. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_(drug).pdf
48. https://www.nature.com/articles/s44323-025-00025-5
49. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1529769/full
50. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822422
51. https://pubmed.ncbi.nlm.nih.gov/39365407/
52. https://clinicaltrials.gov/study/NCT07213349
53. https://www.isrctn.com/ISRCTN63918057
54. https://pmc.ncbi.nlm.nih.gov/articles/PMC11979663/
55. https://www.mypcnow.org/fast-fact/orexin-receptor-antagonists-for-insomnia-in-patients-with-serious-illness/
56. https://ctv.veeva.com/study/daridorexant-for-alzheimer-disease-prevention
57. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_(drug).pdf
58. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710117/
59. https://ctv.veeva.com/study/daridorexant-for-alzheimer-disease-prevention
60. https://www.isrctn.com/pdf/63918057
61. https://www.nature.com/articles/s41398-025-03439-8
62. https://pubmed.ncbi.nlm.nih.gov/40555730/
63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12187915/
64. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_(drug).pdf
65. https://academic.oup.com/sleep/article/47/11/zsae098/7655689
66. https://www.sciencedirect.com/science/article/pii/S1389945725001923
67. https://pubmed.ncbi.nlm.nih.gov/39365407/
68. https://www.nih.gov/news-events/nih-research-matters/insomnia-drug-may-lower-levels-alzheimers-proteins
69. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710117/
70. https://www.isrctn.com/ISRCTN63918057
71. https://www.sciencedirect.com/science/article/abs/pii/S1064748124004809
72. https://www.mypcnow.org/fast-fact/orexin-receptor-antagonists-for-insomnia-in-patients-with-serious-illness/
73. https://pmc.ncbi.nlm.nih.gov/articles/PMC11979663/
74. https://pmc.ncbi.nlm.nih.gov/articles/PMC10990727/
75. https://clinicaltrials.gov/study/NCT07213349
76. https://www.ccjm.org/content/92/1/43
77. https://pubmed.ncbi.nlm.nih.gov/36355586/
78. https://academic.oup.com/jat/advance-article/doi/10.1093/jat/bkaf032/8118879

79. https://valintermed.com/en/blog/informative-review-of-new-drugs-for-insomnia-daridorexant-suvorexant-and-lemborexant/
80. https://www.neurology.org/doi/10.1212/WNL.0000000000009489
81. https://www.psychiatrist.com/jcp/lemborexant-daridorexant-treatment-insomnia-indirect-comparison-using-nnt-nnh-lhh/
82. https://academic.oup.com/ageing/article-abstract/54/Supplement_2/afaf133.092/8185887
83. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1175372/full
84. https://www.youtube.com/watch?v=ZYW-GfbtF2w
85. https://pubmed.ncbi.nlm.nih.gov/36355586/
86. https://pmc.ncbi.nlm.nih.gov/articles/PMC10990727/
87. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1175372/full
88. https://www.psychiatrist.com/jcp/lemborexant-daridorexant-treatment-insomnia-indirect-comparison-using-nnt-nnh-lhh/
89. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_(drug).pdf
90. https://pmc.ncbi.nlm.nih.gov/articles/PMC12187915/
91. https://pmc.ncbi.nlm.nih.gov/articles/PMC11602839/
92. https://pubmed.ncbi.nlm.nih.gov/39365407/
93. https://ctv.veeva.com/study/daridorexant-for-alzheimer-disease-prevention
94. https://www.isrctn.com/pdf/63918057
95. https://www.centre-stopad.com/en/essai-clinique-en-developpement/
96. https://www.clinicaltrials.gov/study/NCT06274528
97. https://www.trialx.com/clinical-trials/listings/286861/dora-and-lp-in-alzheimers-disease-biomarkers/
98. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710307/
99. https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.090830
100. https://www.alzheimers.gov/news/insomnia-drug-may-lower-levels-alzheimers-proteins
101. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.984227/full
102. https://pmc.ncbi.nlm.nih.gov/articles/PMC9929354/
103. https://www.nature.com/articles/s44323-025-00025-5
104. https://jcsm.aasm.org/doi/10.5664/jcsm.7282
105. https://pmc.ncbi.nlm.nih.gov/articles/PMC10990727/
106. https://www.withpower.com/trial/phase-2-alzheimer-disease-9-2025-347b1
107. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Suvorexant-Cognitive-Vitality-For-Researchers.pdf
108. https://www.sciencedirect.com/science/article/pii/S1347861325001070
109. https://www.sciencedirect.com/science/article/abs/pii/S0304394021006261
110. https://www.isrctn.com/ISRCTN63918057
111. https://neurosciencenews.com/alzheimers-sleep-neuropharmacology-23066/
112. https://pmc.ncbi.nlm.nih.gov/articles/PMC11979663/
113. https://pubmed.ncbi.nlm.nih.gov/36897120/

114. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.984227/full
115. https://pmc.ncbi.nlm.nih.gov/articles/PMC2789838/
116. https://pmc.ncbi.nlm.nih.gov/articles/PMC9929354/
117. https://www.science.org/doi/abs/10.1126/science.1180962
118. https://pmc.ncbi.nlm.nih.gov/articles/PMC11710117/
119. https://www.psypost.org/common-sleep-aid-blocks-brain-inflammation-and-tau-buildup-in-alzheimers-model/
120. https://academic.oup.com/sleep/article/39/6/1253/2453979
121. https://pmc.ncbi.nlm.nih.gov/articles/PMC4863214/
122. https://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-040323-031929
123. https://www.springermedizin.de/orexin-receptor-antagonists-for-the-prevention-and-treatment-of-/50076990
124. https://www.nature.com/articles/s44323-025-00025-5
125. https://www.sciencedirect.com/science/article/abs/pii/S1389945724003411
126. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.1025402/full
127. https://www.psychiatryinvestigation.org/upload/pdf/pi-2020-0136.pdf
128. https://jcsm.aasm.org/doi/10.5664/jcsm.7282
129. https://www.alzheimers.gov/news/insomnia-drug-may-lower-levels-alzheimers-proteins
130. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.1004002/full
131. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16212
132. https://en.wikipedia.org/wiki/Orexin_antagonist
133. https://onlinelibrary.wiley.com/doi/10.1111/jsr.13902
134. https://www.sciencedirect.com/science/article/pii/S0091302223000146
135. https://en.wikipedia.org/wiki/Orexin
136. https://www.pnas.org/doi/10.1073/pnas.0400590101
137. https://synapse.patsnap.com/article/what-are-orexin-receptor-antagonists-and-how-do-they-work
138. https://pubmed.ncbi.nlm.nih.gov/15673670/
139. https://www.nature.com/articles/srep41535
140. https://pubmed.ncbi.nlm.nih.gov/26965217/
141. https://www.sleepfoundation.org/sleep-aids/orexins
142. https://pmc.ncbi.nlm.nih.gov/articles/PMC12454320/
143. https://pmc.ncbi.nlm.nih.gov/articles/PMC5815356/
144. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2014.00244/full
145. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1230428/full
146. https://www.pnas.org/doi/10.1073/pnas.1315542111
147. https://pmc.ncbi.nlm.nih.gov/articles/PMC5854806/
148. https://www.sciencedirect.com/science/article/pii/S2211124717300670
149. https://www.sciencedirect.com/science/article/abs/pii/S0196978123000712
150. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2017.00032/full

151. https://pmc.ncbi.nlm.nih.gov/articles/PMC5767117/
152. https://www.sciencedirect.com/science/article/pii/S0896627303003313
153. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.639313/full
154. https://pmc.ncbi.nlm.nih.gov/articles/PMC11458361/
155. https://pubmed.ncbi.nlm.nih.gov/15016085/
156. https://pmc.ncbi.nlm.nih.gov/articles/PMC8923289/
157. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388912/
158. https://en.wikipedia.org/wiki/Melanin-concentrating_hormone
159. https://www.pnas.org/doi/pdf/10.1073/pnas.1315542111
160. https://www.nature.com/articles/s41386-021-01196-y
161. https://pmc.ncbi.nlm.nih.gov/articles/PMC3727095/
162. https://pmc.ncbi.nlm.nih.gov/articles/PMC6729969/
163. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2013.00018/full
164. https://pubmed.ncbi.nlm.nih.gov/15470140/
165. https://www.sciencedirect.com/science/article/abs/pii/S0306452215004819
166. https://pmc.ncbi.nlm.nih.gov/articles/PMC3589707/
167. https://pmc.ncbi.nlm.nih.gov/articles/PMC4345701/
168. https://www.pnas.org/doi/10.1073/pnas.1307389110
169. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1590556/full
170. https://academic.oup.com/endo/article/152/11/4046/2457049
171. https://www.jci.org/articles/view/92008
172. https://www.sciencedirect.com/science/article/pii/S0306452219308620
173. https://pmc.ncbi.nlm.nih.gov/articles/PMC5378779/
174. https://www.sciencedirect.com/science/article/pii/S1550413105000823
175. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2014.00211/full
176. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00176/full
177. https://academic.oup.com/endo/article-abstract/152/11/4046/2457049
178. https://pmc.ncbi.nlm.nih.gov/articles/PMC2875836/
179. https://elifesciences.org/articles/44927
180. https://www.sciencedirect.com/science/article/pii/S0006322325016105
181. https://en.wikipedia.org/wiki/Lateral_hypothalamus
182. https://www.sciencedirect.com/science/article/abs/pii/0149763484900228?via%3Dihub
183. https://onlinelibrary.wiley.com/doi/10.1111/joim.13406
184. https://pubmed.ncbi.nlm.nih.gov/12668217/
185. https://www.sciencedirect.com/topics/neuroscience/delta-sleep-inducing-peptide
186. https://academic.oup.com/sleep/article-abstract/9/1/80/2742926
187. https://pmc.ncbi.nlm.nih.gov/articles/PMC12454320/
188. https://pubmed.ncbi.nlm.nih.gov/17346943/

189. https://academic.oup.com/sleep/article/36/9/1391/2453896
190. https://pmc.ncbi.nlm.nih.gov/articles/PMC3589707/
191. https://pmc.ncbi.nlm.nih.gov/articles/PMC2860674/
192. https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
193. https://academic.oup.com/sleep/article-abstract/15/6/519/2749303
194. https://www.biorxiv.org/content/10.1101/2022.01.30.478401.full
195. https://www.nature.com/articles/s41467-022-31591-y
196. https://pmc.ncbi.nlm.nih.gov/articles/PMC5805467/
197. https://pmc.ncbi.nlm.nih.gov/articles/PMC2632999/
198. https://swolverine.com/en-ca/blogs/blog/dsip-delta-sleep-inducing-peptide-benefits-dosage-and-risks-explained
199. https://phoenixpeptide.com/products/delta-sleep-inducing-peptide-dsip/
200. https://www.droracle.ai/articles/280677/what-peptide-has-the-most-valuable-research-regarding-insomnia
201. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1230428/full
202. https://pubmed.ncbi.nlm.nih.gov/1299794/
203. https://www.sciencedirect.com/science/article/abs/pii/0149763484900228?via%3Dihub
204. https://pmc.ncbi.nlm.nih.gov/articles/PMC5805467/
205. https://academic.oup.com/sleep/article-abstract/9/1/80/2742926
206. https://www.sciencedirect.com/topics/neuroscience/delta-sleep-inducing-peptide
207. https://pubmed.ncbi.nlm.nih.gov/12668217/
208. https://pubmed.ncbi.nlm.nih.gov/1299794/
209. https://pmc.ncbi.nlm.nih.gov/articles/PMC2632999/
210. https://onlinelibrary.wiley.com/doi/10.1111/joim.13406
211. https://www.sciencedirect.com/topics/neuroscience/delta-sleep-inducing-peptide
212. https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.03693.x
213. https://pubmed.ncbi.nlm.nih.gov/2657475/
214. https://pubmed.ncbi.nlm.nih.gov/39706239/
215. https://pmc.ncbi.nlm.nih.gov/articles/PMC5805467/
216. https://pubmed.ncbi.nlm.nih.gov/1814802/
217. https://pmc.ncbi.nlm.nih.gov/articles/PMC5118111/
218. https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
219. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00573/full
220. https://pubmed.ncbi.nlm.nih.gov/11471521/
221. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/delta-sleep-inducing-peptide
222. https://pmc.ncbi.nlm.nih.gov/articles/PMC9852239/
223. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/delta-sleep-inducing-peptide

224. https://particlepeptides.com/en/blog/news/delta-sleep-inducing-peptide-dsip-and-studies
225. https://pubmed.ncbi.nlm.nih.gov/30107169/
226. https://www.tandfonline.com/doi/abs/10.3109/08039488809103215
227. https://www.sciencedirect.com/science/article/pii/0196978189900934
228. https://www.agemanagementmi.com/dsip-peptide
229. https://www.sciencedirect.com/topics/medicine-and-dentistry/delta-sleep-inducing-peptide
230. https://pubmed.ncbi.nlm.nih.gov/17167093/
231. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/04EA29FACB57F0D24E6FCD4B7E54AA00/S0265021501000898a.pdf/delta_sleepinducing_peptide.pdf